Molecular discovery.Biological proof.
Image: Ali Rehman
Molecule to Mechanism Validation
EleganC Bio combines high-resolution structural chemistry with biological proof to transform traditional biological extracts into validated products for the global nutraceutical industry.
Zaka
Co-Founder & Chief Scientist
PhD, University of Georgia CCRC — NMR structural chemistry & C. elegans biological screening
Khizr
Co-Founder & Strategy Lead
Business strategist bringing 16 years of partnership with Zaka to commercialize botanical products
Years Professional Experience
Published Papers & Protocols
Natural extract to licensable product
A rigorous, end-to-end pipeline that transforms raw botanicals into validated assets.
Botanical Source
StartSourcing high-quality traditional botanical raw materials from trusted supply chains.
ExtractionRaw Extract
Initial extraction produces crude botanical concentrates for downstream analysis.
ExtractionCrude Fractions
Systematic fractionation separates the extract into distinct chemical groups for targeted analysis.
SeparationIn-Vivo Validation
Key BiologyC. elegans phenotypic screening provides living-system biological proof at high throughput.
AssayMolecular Fingerprinting
Key Chemistry900 MHz NMR and HSQC spectroscopy reveal the precise molecular structure of active compounds.
ElucidationData Integration
All structural and biological data converge into a comprehensive scientific dossier.
ChemistryValidated Product
EndProprietary data package ready for pre-clinical validation.
ModelingBotanical Source
StartSourcing high-quality traditional botanical raw materials from trusted supply chains.
Raw Extract
Initial extraction produces crude botanical concentrates for downstream analysis.
Crude Fractions
Systematic fractionation separates the extract into distinct chemical groups for targeted analysis.
In-Vivo Validation
Key BiologyC. elegans phenotypic screening provides living-system biological proof at high throughput.
Molecular Fingerprinting
Key Chemistry900 MHz NMR and HSQC spectroscopy reveal the precise molecular structure of active compounds.
Data Integration
All structural and biological data converge into a comprehensive scientific dossier.
Validated Product
EndProprietary data package ready for pre-clinical validation.
Built on Proven Expertise
Backed by rigorous research and decades of domain knowledge.
20+ Years Experience
Combined professional experience in chemistry, biology, and pharmaceutical research
10+ Published Works
Peer-reviewed articles and laboratory protocols in structural chemistry and biology
Ready to Transform YourBotanical IP?
Whether you're an investor seeking the next frontier in nutraceutical science, or a brand looking to validate and protect your formulation — we're ready to talk.
Frequently Asked Questions
Most labs only tell you if a product works; we tell you how it works at a molecular level. We start by fractionating your raw botanical extracts, identifying the active compounds via high-resolution NMR, and then proving their biological effect using C. elegans phenotypic screening. This creates a "Scientific Ground Truth" dossier that you can use for patents, regulatory filings, and premium marketing.
C. elegans (microscopic nematodes) share 60-80% of human metabolic and disease-related genes. Using our high-throughput assays, we can screen hundreds of compounds in a living system in a fraction of the time and cost of mammalian models. It provides "In-Vivo" proof at "In-Vitro" speeds.
Our Technical Audit is a 72-hour deep dive into your current formulation. We review your Certificates of Analysis (COA), ingredient sourcing, and existing scientific literature to identify gaps in claims. You receive a professional report detailing your product's strengths and the specific pathways needed to secure proprietary IP.
Yes. Our end goal is the delivery of a Validated Scientific Dossier. This document integrates our NMR structural data with biological mechanism proof, providing the rigorous technical foundation your legal team needs to file for "Method of Use" or "Composition of Matter" patents.
We offer flexible partnership models. For our Consulting and Audit services, the client owns the resulting report. For our Co-Development and IP Engine partnerships, we work on a licensing or royalty model that allows brands to "rent" or "buy" exclusive rights to the molecular mechanisms we discover in the Bridge Lab.